В статье представлены ключевые подходы к диагностике и лечению фибрилляции предсердий в свете новых Рекомендаций Европейского общества кардиологов 2024 г. по лечению фибрилляции предсердий, разработанных в содружестве c Европейской ассоциацией кардиоторакальных хирургов. Отражены основные изменения, внесенные в новые рекомендации. Подробно рассмотрен инновационный пациенториентированный принцип лечения фибрилляции предсердий — AF-CARE. Дан анализ обновлённой шкалы оценки риска инсульта и системных эмболий CHA₂DS₂-VA. Приведены определения клинической, субклинической, триггер-индуцированной, впервые выявленной, пароксизмальной, персистирующей и постоянной форм фибрилляции предсердий, алгоритмы лечения разных форм фибрилляции предсердий, основанные на выборе медикаментозной терапии с учётом фракции выброса левого желудочка. Большое внимание уделено скринингу и раннему выявлению фибрилляции предсердий. Определены категории пациентов, у которых целесообразно проводить скрининг. Подчёркнута важность ранней диагностики предсердной кардиомиопатии с помощью анализа деформации миокарда предсердий. Сделан акцент на роли своевременного, базирующегося на актуальных рекомендациях лечения коморбидной патологии, такой как хроническая сердечная недостаточность, сахарный диабет, ожирение, обструктивное апноэ сна, артериальная гипертензия и других, с целью профилактики фибрилляции предсердий, а при ее появлении — уменьшения рецидивов.

atrial fibrillationsinus rhythm controlventricular rate controlstroke preventionфибрилляция предсердийконтроль синусового ритмаконтроль частоты желудочковых сокращенийпрофилактика инсульта1.Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi: 10.1093/eurheartj/ehae176 EDN: TPYMAL2.Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):190–260. doi: 10.15829/1560-4071-2021-4594 EDN: FUZAAD3.Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio- thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–349. doi: 10.1093/eurheartj/ehaa612 EDN: SSKKDD4.Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant therapy in elderly patients with atrial fibrillation. Kardiologiia. 2018;58(10):45–52. doi: 10.18087/cardio.2018.10.10177 EDN: YLGHJB5.Novikova ТN. The risk of bleeding minimization with direct oral anticoagulants. Atherothrombosis. 2021;(1):106–126. doi: 10.21518/2307-1109-2021-11-1-106-126 EDN: AOSWXN6.De with RR, Rienstra M, Nguyen BO, et al. Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace. 2020;22:1162–72. doi: 10.1093/europace/euaa123 EDN: EPRZDH7.Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74. doi: org/10.1001/jama.2019.06938.Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27. doi: 10.1056/NEJMoa1707855 EDN: XXDBJJ9.Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310): 1507–1516. doi: 10.1016/s0140-6736(21)01698-6 EDN: PNEUVA10.Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498–506. doi: 10.1016/S0140-6736(21)01637-8 EDN: YGLWVI11.Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129. doi: 10.1056/NEJMoa110557512.Lubitz SA, Yin X, Rienstra M, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015;131(19):1648–1655. doi: 10.1161/CIRCULATIONAHA.114.014058 EDN: YCPEYC13.Wang EY, Hulme OL, Khurshid S, et al. Initial precipitants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol. 2020;13(3):e007716. doi: 10.1161/CIRCEP.119.007716 EDN: ZJUMOR14.Corica B, Romiti GF, Basili S, Proietti M. Prevalence of new-onset atrial fibrillation and associated outcomes in patients with sepsis: a systematic review and meta-analysis. J Pers Med. 2022;12(4):547. doi: 10.3390/jpm12040547 EDN: XDNZQR15.Bedford JP, Ferrando-Vivas P, Redfern O, et al. New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur Heart J Acute Cardiovasc Care. 2022;11(8):620–628. doi: 10.1093/ehjacc/zuac080 EDN: PLMSJN16.1Coats AJS, Heymans S, Farmakis D, et al. Atrial disease and heart failure: the common soil hypothesis proposed by the heart failure association of the European Society of Cardiology. Eur Heart J. 2022:43(9):863–867. doi: 10.1093/eurheartj/ehab834 EDN: ZSWEFQ17.Schnabel RB, Marinelli EA, Arbelo E, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace. 2023;25(1):6–27. doi: 10.1093/europace/euac062 EDN: JFQFMB18.Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/ APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10): 1455–1490. doi: 10.1093/europace/euw161 EDN: XUQHUD19.19. Pathan F, D'Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007 EDN: XZTNYZ20.Novikova TN, Andreeva AE, Bitakova FI, et al. Multifaces of hypertrophic cardiomyopathy: a case of transformation of hypertrophic phenotype into dilated. Cardiac Arrhythmias. 2024;4(1):31–41. doi: 10.17816/cardar630134 EDN: MDUOTK21.Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2 DS2 –VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003–9. doi: 10.1002/clc.23257 EDN: BKBIBI22.Wu VC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart. 2020;106(7):534–540. doi: 10.1136/heartjnl-2019-315065 EDN: THDVZU23.Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost. 2012;10(9):1745–1751. doi: 10.1111/j.1538-7836.2012.04853.x EDN: WUSZOX24.Antonenko K, Paciaroni M, Agnelli G, et al. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: results from the RAF study (early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation). Eur Stroke J. 2017;2(1):46–53. doi: 10.1177/2396987316679577 EDN: VJGUBH25.Chung S, Kim TH, Uhm JS, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]). Am J Cardiol. 2020;125(1):68–75. doi: 10.1016/j.amjcard.2019.09.035 EDN: QRXFNN26.Uhm JS, Kim J, Yu HT, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail. 2021;8(2):1582–9. doi: 10.1002/ehf2.13264 EDN: MFEEUA27.McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013;6(3):451–60. doi: 10.1161/CIRCHEARTFAILURE.112.000143 EDN: RIMJIZ28.McEvoy JW, Touyz RM, McCarthy CP, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. doi: 10.1093/eurheartj/ehae17829.Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(11): 1233–1245. doi: 10.1016/j.jacc.2018.05.07630.Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrillation project. Stroke. 2015;46(1):143–150. doi: 10.1161/STROKEAHA.114.007199 EDN: YMYQJF31.American Diabetes Association (ADA). Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(S1):S17–S38. doi: 10.2337/dc22-s002 EDN: VUUZUZ32.Steensig K, Olesen KKW, Thim T, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost. 2018;118(12):2162–2170. doi: 10.1055/s-0038-1675401 EDN: WYUPXD33.Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol. 1998;31(7):1622–1626. doi: 10.1016/S0735–1097(98)00146-6 EDN: AAVLEX34.Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. J Am Soc Echocardiogr. 1996;9(4):556–566.35.35. Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation. 2019;12(4):2207. doi: 10.4022/jafib.220736.Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465–472. doi: 10.1136/heartjnl-2013-30427637.Guttmann OP, Pavlou M, O'Mahony C, et al. Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail. 2015;17(8):837–845. doi: 10.1002/ejhf.316 EDN: PTBPNY38.Vilches S, Fontana M, Gonzalez-Lopez E, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387–96. doi: 10.1002/ejhf.2566 EDN: GMQSXF39.Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart. 2017;103(19):1496–1501. doi: 10.1136/heartjnl-2016-31072040.Hirota T, Kubo T, Baba Y, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort-results from Kochi RYOMA study. Circ J. 2019;83(8):1747–1754. doi: 10.1253/circj.CJ-19-018641.Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY). 2020;12(23):24219–27. doi: 10.18632/aging.104133 EDN: YVPBCM42.Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171–2187. doi: 10.1055/s-0038-1675400 EDN: TFLAOB43.Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9): 555–561. doi: 10.1002/clc.22435 EDN: XYQXPX44.Caldeira D, Costa J, Fernandes RM, et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014;40(3):277–284. doi: 10.1007/s10840-014-9930-y EDN: BXQBUE45.Zeng J, Yu P, Cui W, et al. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore). 2020;99(25):e20782. doi: 10.1097/md.0000000000020782 EDN: KVDBXU46.Wang C, Yu Y, Zhu W, et al. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget. 2017;8(65):109703–109711. doi: 10.18632/oncotarget.19858 EDN: JOEFSP47.Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011;90(10):1191–1200. doi: 10.1007/s00277-011-1267-3 EDN: XZADDB48.Hilkens NA, Algra A, Greving JP. Predicting major bleeding in ischemic stroke patients with atrial fibrillation. Stroke. 2017;48(11):3142–3144. doi: 10.1161/STROKEAHA.117.019183 EDN: TNNGOO49.Dalgaard F, Pieper K, Verheugt F, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 2019;9(11):e033283. doi: 10.1136/bmjopen-2019-033283 EDN: PCWXHL50.Mori N, Sotomi Y, Hirata A, et al. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol. 2019;124(7):1044–1048. doi: 10.1016/j.amjcard.2019.07.005 EDN: LRXXTL51.Yao X, Gersh BJ, Sangaralingham LR, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol. 2017;120(9):1549–1556. doi: 10.1016/j.amjcard.2017.07.051 EDN: GIQXWJ52.Nelson WW, Laliberté F, Patel AA, et al. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin. 2017;33(4): 631–638. doi: 10.1080/03007995.2016.1275936 EDN: FRRTRC53.Hijazi Z, Lindbäck J, Oldgren J, et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023;261:55–63. doi: 10.1016/j.ahj.2023.03.012 EDN: EKFHGC